上海医药出海突破:耗时四年,替格瑞洛片成功打入美国市场

瑞财经
Nov 06, 2025

财中社11月6日电上海医药(601607/02607)发布公告,公司下属常州制药厂有限公司收到美国食品药品监督管理局的通知,其关于替格瑞洛片的简略新药申请已获得最终批准上市。该药品用于急性冠脉综合征患者,降低血栓性心血管事件的发生率。常州制药厂于2021年5月向美国FDA提出该药品的ANDA申请,并于近期获得批准。截至公告日,公司针对该药品已投入研发费用约967万元。根据IMS数据库显示,2024...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10